CLEVELAND, May 25, 2021 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that American Hospital in Istanbul, Turkey, has purchased a MRIdian MRI-guided radiation therapy system to expand their radiotherapy and stereotactic body radiation therapy (SBRT) programs. The MD Anderson Radiation Treatment Center at the American Hospital offers world-class, cutting-edge technology to facilitate customized approaches to each patient's diagnosis and treatment.
The addition of MRIdian further supports American Hospital's mission by enabling personalized on-table adaptive radiotherapy to address daily anatomical changes. MRIdian will enable American Hospital to offer the latest MRI-guided radiation therapy technology to patients throughout the region seeking personalized treatment for cancers including lung, liver, prostate, pancreas, and breast.
"As one of the pioneers in SBRT, we selected MRIdian as the next logical step in maintaining and advancing our precision radiotherapy program. MRIdian will allow us to adapt and customize doses with tighter margins and deliver ablative treatments to treat tumors in difficult sites while minimizing associated toxicities," said Professor Uğur Selek, M.D., FASTRO, head of the radiation oncology department at American Hospital.
Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.
"We are pleased to welcome American Hospital to the global community of centers adopting MRIdian to offer personalized treatment to a broader population of cancer patients, including those who were previously considered untreatable," said Martin Fuss, M.D., chief medical officer at ViewRay. "As a member of the MD Anderson Cancer Network, American Hospital has a reputation for offering the most innovative treatment options available. The addition of MRIdian MRI-guided radiation therapy further advances their position as a leader in cancer care."
The MRIdian system provides oncologists outstanding anatomical visualization through diagnostic-quality MR images and the ability to adapt to the targeted cancer in real-time. This combination allows physicians to define tight treatment margins based on the daily anatomy to support the delivery of ablative radiation doses in five or fewer treatment sessions, without relying on fiducial markers. By enabling continuous tracking of the target and surrounding healthy tissue, MRIdian facilitates the automatic gating of the radiation beam if the target moves outside the user-defined margins. This allows for delivery of the prescribed dose to the target, while sparing surrounding healthy tissue and critical structures, which results in minimizing toxicities typically associated with conventional radiation therapy.